University of Oxford

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1096-01-01

Employees: 10K

Market Cap: -

Website: http://www.ox.ac.uk

Clinical Trials

Iron Status and Human Metabolism

Not Applicable

Completed

Conditions: Iron Deficiency

Interventions: Drug: Sodium chloride (placebo)
Drug: Ferric carboxymaltose

First Posted Date: 2014-12-04

Last Posted Date: 2022-07-19

Lead Sponsor: University of Oxford

Target Recruit Count: 29

Registration Number: NCT02308449

Locations: 🇬🇧
University of Oxford OCMR & CCRF, John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom

PATH-2: Platelet Rich Plasma in Achilles Tendon Healing

Not Applicable

Completed

Conditions: Achilles Tendon Rupture

Interventions: Procedure: PRP Injection into Achilles tendon rupture gap
Procedure: Imitation Injection into Achilles tendon rupture gap

First Posted Date: 2014-11-27

Last Posted Date: 2021-05-05

Lead Sponsor: University of Oxford

Target Recruit Count: 230

Registration Number: NCT02302664

Locations: 🇬🇧
Basildon University Hospital, Basildon, United Kingdom
🇬🇧
University Hospital Coventry, Coventry, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom

and more 15 locations

A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.

Phase 1

Conditions: Ebola Virus Disease

Interventions: Biological: VSV-ZEBOV

First Posted Date: 2014-11-21

Last Posted Date: 2016-04-14

Lead Sponsor: University of Oxford

Target Recruit Count: 40

Registration Number: NCT02296983

Locations: 🇰🇪
KEMRI Wellcome Trust Research Programme, Kilifi, Coast, Kenya

Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering

Not Applicable

Completed

Conditions: Speech Disorders
Stuttering
Fluency Disorders

Interventions: Behavioral: Fluency Training
Device: Anodal TDCS

First Posted Date: 2014-11-11

Last Posted Date: 2017-01-31

Lead Sponsor: University of Oxford

Target Recruit Count: 30

Registration Number: NCT02288598

Locations: 🇬🇧
University of Oxford, Oxford, United Kingdom

A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Phase 1

Completed

Conditions: Plasmodium Falciparum Malaria

Interventions: Biological: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)
Biological: ChAd63 ME-TRAP (5 x 10^10 vp)
Biological: RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)
Biological: MVA ME-TRAP (2 x 10^8 pfu)

First Posted Date: 2014-09-30

Last Posted Date: 2015-12-03

Lead Sponsor: University of Oxford

Target Recruit Count: 48

Registration Number: NCT02252640

Locations: 🇬🇧
NIHR WTCRF, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧
NIHR/Wellcome Trust Imperial CRF, Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom

and more 1 locations

Rotavirus Vaccine in Premature Babies

Completed

Conditions: Gastroenteritis

First Posted Date: 2014-09-29

Last Posted Date: 2017-05-09

Lead Sponsor: University of Oxford

Target Recruit Count: 20

Registration Number: NCT02252029

Locations: 🇬🇧
Department of Paediatrics, University of Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧
Oxford University Hospitals NHS Trust, Oxford, United Kingdom

Reformulated F75 Milk to Treat Severe Acute Malnutrition

Phase 2

Completed

Conditions: Malnutrition
Diarrhoea
Metabolic Disturbance

Interventions: Dietary Supplement: Standard F75 Milk
Dietary Supplement: Modified F75 Milk

First Posted Date: 2014-09-22

Last Posted Date: 2016-04-14

Lead Sponsor: University of Oxford

Target Recruit Count: 842

Registration Number: NCT02246296

Locations: 🇰🇪
Kilifi County Hospital, Kilifi, Coast, Kenya
🇲🇼
Queen Elizabeth Hospital- Study site, Blantyre, Malawi
🇰🇪
Coast Provincial General Hospital - Study site, Mombasa, Kenya

A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

Phase 1

Completed

Conditions: Ebola
Ebola Zaire

Interventions: Biological: cAd3-EBO Z at 5 x 10^10 vp
Biological: cAd3-EBO Z at 1 x 10^10 vp
Biological: cAd3-EBO Z at 2.5 x 10^10 vp
Biological: 4.4x10^8 TCID50s MVA-BN® Filo
Biological: 2.2x10^8 TCID50s MVA-BN® Filo
Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo

First Posted Date: 2014-09-16

Last Posted Date: 2018-07-06

Lead Sponsor: University of Oxford

Target Recruit Count: 91

Registration Number: NCT02240875

Locations: 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom

Causes and Factors Associated With Outcomes in Community-acquired Sepsis and Severe Sepsis in Northeast Thailand

Completed

Conditions: Severe Sepsis
Sepsis

First Posted Date: 2014-08-15

Last Posted Date: 2017-11-01

Lead Sponsor: University of Oxford

Target Recruit Count: 5020

Registration Number: NCT02217592

Locations: 🇹🇭
Sappasithiprasong Hospital, Ubon Ratchathani, Thailand

Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Dihydroartemisinin-piperaquine
Drug: Chloroquine

First Posted Date: 2014-07-17

Last Posted Date: 2015-11-03

Lead Sponsor: University of Oxford

Target Recruit Count: 16

Registration Number: NCT02192944

Locations: 🇹🇭
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy